全文获取类型
收费全文 | 47496篇 |
免费 | 3540篇 |
国内免费 | 1965篇 |
专业分类
耳鼻咽喉 | 168篇 |
儿科学 | 830篇 |
妇产科学 | 490篇 |
基础医学 | 6850篇 |
口腔科学 | 509篇 |
临床医学 | 3703篇 |
内科学 | 13422篇 |
皮肤病学 | 639篇 |
神经病学 | 3163篇 |
特种医学 | 912篇 |
外国民族医学 | 2篇 |
外科学 | 3714篇 |
综合类 | 5211篇 |
现状与发展 | 5篇 |
预防医学 | 2840篇 |
眼科学 | 878篇 |
药学 | 6143篇 |
6篇 | |
中国医学 | 1534篇 |
肿瘤学 | 1982篇 |
出版年
2023年 | 470篇 |
2022年 | 911篇 |
2021年 | 1180篇 |
2020年 | 1165篇 |
2019年 | 1832篇 |
2018年 | 1800篇 |
2017年 | 1618篇 |
2016年 | 1592篇 |
2015年 | 1751篇 |
2014年 | 2857篇 |
2013年 | 3309篇 |
2012年 | 2607篇 |
2011年 | 2896篇 |
2010年 | 2185篇 |
2009年 | 2108篇 |
2008年 | 2097篇 |
2007年 | 2309篇 |
2006年 | 2035篇 |
2005年 | 1782篇 |
2004年 | 1570篇 |
2003年 | 1450篇 |
2002年 | 1224篇 |
2001年 | 1097篇 |
2000年 | 935篇 |
1999年 | 842篇 |
1998年 | 721篇 |
1997年 | 773篇 |
1996年 | 579篇 |
1995年 | 581篇 |
1994年 | 501篇 |
1993年 | 381篇 |
1992年 | 333篇 |
1991年 | 263篇 |
1990年 | 202篇 |
1989年 | 180篇 |
1988年 | 150篇 |
1987年 | 131篇 |
1985年 | 466篇 |
1984年 | 566篇 |
1983年 | 453篇 |
1982年 | 418篇 |
1981年 | 406篇 |
1980年 | 363篇 |
1979年 | 324篇 |
1978年 | 276篇 |
1977年 | 208篇 |
1976年 | 247篇 |
1975年 | 250篇 |
1974年 | 196篇 |
1973年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
3.
4.
5.
目的:探讨老年人桡骨远端C型骨折的手术治疗与非手术治疗的疗效差异,评价两种方法的优缺点。方法回顾性分析2009-12—2011-12收治的老年桡骨远端C型骨折68例,按照治疗方法分为A组(手术组)及B组(非手术组),统计分析两组患者的临床资料。结果 A组33例, B组35例,平均随访21.5个月。两组患者的年龄、骨折类型均无差异(P>0.05);术后影像学指标A组优于B组,骨折愈合时间B组优于A组,治疗成本A组大于B组(P<0.05);Cooney评分早期A组优于B组,1年后两组无差异,两组的并发症无差异(P>0.05)。结论老年人桡骨远端C型骨折手术治疗较非手术治疗可获得更好的复位及早期功能,但远期功能恢复无差异。 相似文献
6.
7.
8.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
9.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
10.
《Journal of labelled compounds & radiopharmaceuticals》2006,49(4):339-343
Condensation of thiourea 1 with diethyl malonate 2 in the presence of sodium methoxide furnished 4,6‐dihydroxy‐2‐mercaptopyrimidine 3 . Compound 3 on methylation with diazomethane followed by oxidation with H5IO6/CrO3 in ethyl acetate gave 4,6‐dimethoxy‐2‐methylsulphonylpyrimidine 5 . Compound 5 on condensation with 2‐mercapto‐6‐chlorobenzoic acid in the presence of a phase transfer catalyst, tetrabutylammonium bromide and sodium carbonate gave the title compound – pyrithiobac‐sodium 6 with an overall yield of > 35% starting from thiourea. Following the above standardized procedure, using [14C]‐thiourea in lieu of thiourea, 14C labelled product 6 , was synthesized with an overall radiochemical yield > 30% (with respect to [14C]‐thiourea) for further evaluations of environmental fate of 6 , in soils and plants. Copyright © 2006 John Wiley & Sons, Ltd. 相似文献